MTND1P16

Across TCGA pan-cancer cohorts, MTND1P16 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTND1P16 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MTND1P16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND1P16 expression acts as an unfavorable survival marker, although some lineages such as READ show a favorable association.

KIRC, BRCA, and THCA are the cancer types where MTND1P16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	IV	0.249	0.642	.001	48	view →
BRCA	DFS	Tertile	All	0.570	1.000	.033	36	view →
THCA	DFS	Tertile	IV	0.126	0.805	.002	36	view →
COAD	OS	Tertile	III,IV	0.202	0.694	.013	27	view →
HNSC	DFS	Tertile	IV	0.212	0.574	.035	9	view →
LGG	OS	Tertile	All	0.655	0.842	.040	6	view →
STAD	DFS	Tertile	All	0.563	0.737	.043	3	view →
READ	DFS	Tertile	II,III,IV	1.000	0.455	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTND1P16–KIRC (DFS)

Open the KIRC breakdown →